These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9328370)

  • 1. Impact of capitation on free-standing dialysis facilities: can you survive?
    McMurray SD; Miller J
    Am J Kidney Dis; 1997 Oct; 30(4):542-8. PubMed ID: 9328370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of inpatient and outpatient Medicare allowable charges for continuous ambulatory peritoneal and center hemodialysis patients: a single-center study.
    Prowant BF; Kappel DF; Campbell A
    Am J Kidney Dis; 1986 Oct; 8(4):248-52. PubMed ID: 3532772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Medicare cost of renal dialysis. Evidence from a statistical cost function.
    Dor A; Held PJ; Pauly MV
    Med Care; 1992 Oct; 30(10):879-91. PubMed ID: 1405794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare program; end-stage renal disease prospective payment system. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
    Goeree R; Manalich J; Grootendorst P; Beecroft ML; Churchill DN
    Clin Invest Med; 1995 Dec; 18(6):455-64. PubMed ID: 8714789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. For-profit versus not-for-profit dialysis care for children with end stage renal disease.
    Furth SL; Hwang W; Neu AM; Fivush BA; Powe NR
    Pediatrics; 1999 Sep; 104(3 Pt 1):519-24. PubMed ID: 10469779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of diagnosis-related groups on the cost of hospitalization for end-stage renal disease patients at Rhode Island Hospital from 1987 to 1990.
    Chazan JA; London MR; Pono L
    Am J Kidney Dis; 1992 Jun; 19(6):523-5. PubMed ID: 1595699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
    Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
    Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
    Iglehart JK
    N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.
    Hooi LS; Lim TO; Goh A; Wong HS; Tan CC; Ahmad G; Morad Z
    Nephrology (Carlton); 2005 Feb; 10(1):25-32. PubMed ID: 15705178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study.
    Sibbel S; Sato R; Hunt A; Turenne W; Brunelli SM
    BMC Nephrol; 2016 Dec; 17(1):199. PubMed ID: 27955633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial effect of clinical decisions: case study of a dialysis center.
    Balas EA; Hicks LL; Stone JV; Ponferrada LP; West DA
    J Med Syst; 1995 Dec; 19(6):465-74. PubMed ID: 8750377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Freestanding Dialysis Facility Size and Medicare Quality Incentive Program Performance Scores.
    Ajmal F; Probst J; Brooks J; Hardin J; Qureshi Z
    Am J Nephrol; 2019; 49(1):64-73. PubMed ID: 30557871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.
    Hirth RA; Held PJ; Orzol SM; Dor A
    Health Serv Res; 1999 Feb; 33(6):1567-92. PubMed ID: 10029498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost analysis of dialysis modalities in Italy.
    Tediosi F; Bertolini G; Parazzini F; Mecca G; Garattini L
    Health Serv Manage Res; 2001 Feb; 14(1):9-17. PubMed ID: 11246787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring kidney dialysis costs in the United States: a scoping review.
    Stewart F; Kistler K; Du Y; Singh RR; Dean BB; Kong SX
    J Med Econ; 2024; 27(1):618-625. PubMed ID: 38605648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.